Neurological Associates of Albany

Albany, New York 12212

1 studies enrolling now · 16 studies all time

What they study most

AD, Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 17, Alzheimer Disease 18

Studies at this site

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects — Stopped early
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) — Running, not enrolling
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects — Completed
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) — Running, not enrolling
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease — Stopped early
Open-label Extension for Phase 3 Clinical Trials of Simufilam — Stopped early
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD) — Completed
Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI — Stopped early
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015) — Enrolling by invitation
A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease — Completed
Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD) — Stopped early
Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease — Completed
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease — Status unconfirmed
An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type — Completed
Effects of ONO-2506PO in Patients With Alzheimer's Disease — Completed
Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease — Status unconfirmed